Skip to main content
Videos

Improving Survival, Remission Rates Among Patients With AML Treated With New Drug Combo

php logoKeith Pratz, MD, associate professor of medicine at the Abramson Comprehensive Cancer Center at University of Pennsylvania, discusses the phase III VIALE-A study that demonstrated a reduction in the risk of death in patients with AML among other positive results. 

 

Reference:

DiNardo, C.D., Jonas, B.A., et al. A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax With Azacitidine Vs. Azacitidine In Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible For Intensive Therapy: The Phase 3 VIALE-A Trial. (2020).